PERCEPTIVE ADVISORS LLC
Q2 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001224962
· CRD 154703
· SEC-registered investment adviser
$4.2B Reported Value Total
PERCEPTIVE ADVISORS reports 29 total accounts under management (AUM). There are 29 discretionary accounts valued at $9,715,749,804, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
29 funds
· $11.7B gross asset value
Hedge Fund: $10.5B · Venture Capital Fund: $713.7M · Private Equity Fund: $480.2M · Other: $14.7M
Source: Form ADV filed 2026-07-13
Reported value
$4.2B
Quarter over quarter
-14.9%
Holdings
107
Top-10 concentration
47.2%
Key People
Form ADV owners & control persons
Joseph Eric Edelman
CHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER
Adam Leo Stone
CHIEF INVESTMENT OFFICER
Shmuel Mordechai Cohn
CHIEF FINANCIAL OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $4.2B |
| Positions | 107 |
| Change in reported value | -27.4% |
| New positions | 21 |
| Exited positions | 19 |
| Position turnover | 31.8% |
| Top-10 concentration | 47.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
101 | $6.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
91 | $5.1B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
111 | $5.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
90 | $3.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
82 | $2.7B |
|
Q1 2025 13F
Filed May 15, 2025
|
86 | $2.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
97 | $3.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
102 | $4.7B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
107 | $4.2B |
|
Q1 2024 13F
Filed May 15, 2024
|
105 | $5.7B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
97 | $4.5B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
87 | $3.0B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
88 | $3.5B |
|
Q1 2023 13F
Filed May 15, 2023
|
98 | $3.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
94 | $3.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
113 | $3.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
107 | $3.2B |
|
Q1 2022 13F
Filed May 16, 2022
|
131 | $5.0B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
140 | $6.5B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
133 | $6.9B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CERE CEREVEL THERAPEUTICS HLDNG I | $441.4M | 10.63% |
| 2 | FOLD AMICUS THERAPEUTICS INC | $278.3M | 6.7% |
| 3 | ACLX ARCELLX INC | $214.7M | 5.17% |
| 4 | IOVA IOVANCE BIOTHERAPEUTICS INC | $208.0M | 5.01% |
| 5 | NUVL NUVALENT INC | $193.4M | 4.66% |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | $141.5M | 3.41% |
| 7 | PCVX VAXCYTE INC | $140.6M | 3.39% |
| 8 | SLNO SOLENO THERAPEUTICS INC | $130.8M | 3.15% |
| 9 | ITCI INTRA-CELLULAR THERAPIES INC | $117.6M | 2.83% |
| 10 | IMTX IMMATICS N.V | $94.0M | 2.26% |
| 11 | NBIX NEUROCRINE BIOSCIENCES INC | $89.5M | 2.16% |
| 12 | APGE APOGEE THERAPEUTICS INC | $82.9M | 2.0% |
| 13 | MDGL MADRIGAL PHARMACEUTICALS INC | $74.1M | 1.79% |
| 14 | AORT ARTIVION INC | $71.7M | 1.73% |
| 15 | SYRE SPYRE THERAPEUTICS INC | $71.3M | 1.72% |
| 16 | CRNX CRINETICS PHARMACEUTICALS IN | $66.1M | 1.59% |
| 17 | EOLS EVOLUS INC | $62.4M | 1.5% |
| 18 | SWTX SPRINGWORKS THERAPEUTICS INC | $62.3M | 1.5% |
| 19 | CRGX CARGO THERAPEUTICS INC | $60.5M | 1.46% |
| 20 | ATXS ASTRIA THERAPEUTICS INC | $59.0M | 1.42% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.